Fexofenadine Overcomes Osimertinib Resistance by Inhibiting c‐Met in Non‐Small Cell Lung Cancer

ABSTRACT Osimertinib is the only third‐generation EGFR tyrosine kinase inhibitor clinically approved for first‐line treatment of advanced NSCLC patients harboring EGFR mutations. However, drug resistance severely hinders its clinical efficacy. Acquired MET amplification is an important mechanism cau...

Full description

Bibliographic Details

Published in:	MedComm – Oncology
Main Authors:	Kenneth K. W. To, Kwong‐Sak Leung, William C. Cho
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Subjects:	DRAR‐CPI epithelial‐mesenchymal transition fexofenadine Met osimertinib
Online Access:	https://doi.org/10.1002/mog2.70019